These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells. Jenkins MH; Croteau W; Mullins DW; Brinckerhoff CE Matrix Biol; 2015 Oct; 48():66-77. PubMed ID: 25989506 [TBL] [Abstract][Full Text] [Related]
28. Update on BRAF and MEK inhibition for treatment of melanoma in metastatic, unresectable, and adjuvant settings. Broman KK; Dossett LA; Sun J; Eroglu Z; Zager JS Expert Opin Drug Saf; 2019 May; 18(5):381-392. PubMed ID: 30977681 [TBL] [Abstract][Full Text] [Related]
29. Concomitant Inhibition of PI3Kβ and BRAF or MEK in PTEN-Deficient/BRAF-Mutant Melanoma Treatment: Preclinical Assessment of SAR260301 Oral PI3Kβ-Selective Inhibitor. Bonnevaux H; Lemaitre O; Vincent L; Levit MN; Windenberger F; Halley F; Delorme C; Lengauer C; Garcia-Echeverria C; Virone-Oddos A Mol Cancer Ther; 2016 Jul; 15(7):1460-71. PubMed ID: 27196754 [TBL] [Abstract][Full Text] [Related]
30. Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. Johnson DB; Menzies AM; Zimmer L; Eroglu Z; Ye F; Zhao S; Rizos H; Sucker A; Scolyer RA; Gutzmer R; Gogas H; Kefford RF; Thompson JF; Becker JC; Berking C; Egberts F; Loquai C; Goldinger SM; Pupo GM; Hugo W; Kong X; Garraway LA; Sosman JA; Ribas A; Lo RS; Long GV; Schadendorf D Eur J Cancer; 2015 Dec; 51(18):2792-9. PubMed ID: 26608120 [TBL] [Abstract][Full Text] [Related]
31. Mitogen-activated protein kinase (MEK) inhibitors to treat melanoma alone or in combination with other kinase inhibitors. Faghfuri E; Nikfar S; Niaz K; Faramarzi MA; Abdollahi M Expert Opin Drug Metab Toxicol; 2018 Mar; 14(3):317-330. PubMed ID: 29363351 [TBL] [Abstract][Full Text] [Related]
32. BRAF and MEK inhibition for the treatment of advanced BRAF mutant melanoma. Richman J; Martin-Liberal J; Diem S; Larkin J Expert Opin Pharmacother; 2015 Jun; 16(9):1285-97. PubMed ID: 26001180 [TBL] [Abstract][Full Text] [Related]
33. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion-Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT Lancet Oncol; 2018 May; 19(5):603-615. PubMed ID: 29573941 [TBL] [Abstract][Full Text] [Related]
34. Discovery of a novel pan-RAF inhibitor with potent anti-tumor activity in preclinical models of BRAF Hong SP; Ahn SK Life Sci; 2017 Aug; 183():37-44. PubMed ID: 28645859 [TBL] [Abstract][Full Text] [Related]
35. BRAF as a target for cancer therapy. Dienstmann R; Tabernero J Anticancer Agents Med Chem; 2011 Mar; 11(3):285-95. PubMed ID: 21426297 [TBL] [Abstract][Full Text] [Related]
36. Activity and Resistance of a Brain-Permeable Paradox Breaker BRAF Inhibitor in Melanoma Brain Metastasis. Bonfill-Teixidor E; Iurlaro R; Handl C; Wichmann J; Arias A; Cuartas I; Emmenegger J; Romagnani A; Mangano L; Lorber T; Berrera M; Godfried Sie C; Köchl F; Eckmann J; Feddersen R; Kornacker M; Schnetzler G; Cicuendez M; Cordero E; Topczewski TE; Ferres-Pijoan A; González J; Martínez-Ricarte F; Muñoz-Couselo E; Tabernero J; Bischoff JR; Pettazzoni P; Seoane J Cancer Res; 2022 Jul; 82(14):2552-2564. PubMed ID: 35584009 [TBL] [Abstract][Full Text] [Related]
37. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT Lancet Oncol; 2018 Oct; 19(10):1315-1327. PubMed ID: 30219628 [TBL] [Abstract][Full Text] [Related]
38. The c-Jun/RHOB/AKT pathway confers resistance of BRAF-mutant melanoma cells to MAPK inhibitors. Delmas A; Cherier J; Pohorecka M; Medale-Giamarchi C; Meyer N; Casanova A; Sordet O; Lamant L; Savina A; Pradines A; Favre G Oncotarget; 2015 Jun; 6(17):15250-64. PubMed ID: 26098773 [TBL] [Abstract][Full Text] [Related]
39. Tan J; Liu R; Zhu G; Umbricht CB; Xing M Proc Natl Acad Sci U S A; 2020 Jul; 117(27):15846-15851. PubMed ID: 32561648 [TBL] [Abstract][Full Text] [Related]
40. Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma. Ma XH; Piao SF; Dey S; McAfee Q; Karakousis G; Villanueva J; Hart LS; Levi S; Hu J; Zhang G; Lazova R; Klump V; Pawelek JM; Xu X; Xu W; Schuchter LM; Davies MA; Herlyn M; Winkler J; Koumenis C; Amaravadi RK J Clin Invest; 2014 Mar; 124(3):1406-17. PubMed ID: 24569374 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]